genedrive plc (GDR)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 1.000 |
|---|---|
| 52-week range | 0.425 – 1.550 |
| Return, 1 month / 3 months | −16.7% / −4.8% |
| Return, 1 year / 3 years | +124.7% / −88.4% |
| Trend | Below its 200-day average |
| RSI (14) | 31 |
| Volatility (1 year) | 80.1% |
| Worst drawdown (1 year) | -29.6% |
| Average daily value traded | 4.60M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
genedrive plc is a molecular diagnostics company based in Manchester, United Kingdom. It develops and supplies rapid genetic testing platforms and tests that healthcare providers use at the point of care, including assays that help guide treatment decisions for patients. Its customers are mainly hospitals, clinics and healthcare organisations that need quick results close to the patient. The company combines its testing instruments with disposable test cartridges and works on diagnostic applications in areas such as infectious disease and drug response.
genedrive plc trades under the code GDR on the London Stock Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
genedrive plc (GDR) trades on the London Stock Exchange in UK. It last closed at GBX 1.000 on 27 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 2,110 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 124.7% and over the last three months it fell 4.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 44 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.0% | ||
| From 52-week high | -28.6% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -4.8% | ||
| 6-month return | 2.6% | ||
| 12-month return, skipping the last month | 169.7% | ||
| Stability (higher is calmer) | 30 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 80.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.6% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 4.60M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −7.0% |
|---|---|
| 1 month | −16.7% |
| 3 months | −4.8% |
| 6 months | +2.6% |
| 1 year | +124.7% |
| 3 years | −88.4% |
| 5 years | −95.5% |
Signals
| 50-day / 200-day average | 1.215 / 1.124 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.108 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.